$eBay (EBAY.US)$ $Meta Platforms (FB.US)$ $Lululemon Athletica (LULU.US)$ $HubSpot (HUBS.US)$
Jefferies: resume tracking eBay (EBAY.O), hold the rating, and raise the target price from US$67 to US$83.
HSBC Research: Raise the target price of Facebook (FB.O) from US$275 to US$300.
Stifel: Raise the target price of HubSpot from US$650 to US$750
JPMorgan Chase: Lowered the target price of FedEx (FDX.N) from US$366 to US$346.
Royal Bank of Canada: resume tracking Halliburton (HAL.N), the rating outperforms the market, and the target price is US$27.
US Center for Financial Research and Analysis: Raise the target price of DocuSign (DOCU.O) by US$40 to US$300.
Loop Capital: I am optimistic about Lyft and give it a "Buy" rating with a target price of US$80
Piper Sandler: Raise the target price of Lululemon (LULU.O) from US$446 to US$481.
MassMutual Securities: Maintain the “Buy” rating of GSMG.US and raise the target price from US$6.50 to US$7.50
Article excerpted from the US Stock Research Agency

Shares of $Novavax (NVAX.US)$ were jumping 9.7% on Thursday.
$Novavax (NVAX.US)$ and its partner Serum Institute of India have applied to the World Health Organization for an emergency use listing of Novavax's COVID-19 vaccine.
Novavax has been prioritizing regulatory submissions to low- and middle-income countries after falling behind in the race for authorization in the United States and Europe, which have already vaccinated most of their residents.
The attention to the vaccine stocks has been decreasing in recent days. Maybe the positive news for Novavax can motivate some investors to pile back into the vaccine stock. Some of their strong performance since the outbreak of COVID-19 may draw your attention.
Let's take a look:
NVAX
Pfizer
Moderna
BioNTech
Most of them are seeing some pretty hefty gains, $Moderna (MRNA.US)$ even increased more than 1,400%. Some investors see their potential and achieved "financial freedom" lol.
BTW even though you don't want to put your bets in the sector, you may already have more exposure to the vaccine industry than you realize, in diluted form. In the U.S., $Moderna (MRNA.US)$ was added to the $S&P 500 Index (.SPX.US)$ in July, and $Johnson & Johnson (JNJ.US)$ and $Pfizer (PFE.US)$ are among the top 25 stocks in the index. That means they’re included in many index funds, ETFs and retirement investments.
Is the news going to be a boost to the whole vaccine sector? What are your thoughts about vaccine stocks? Vote and comment to tell all the mooers!
Source:
How to Invest in the Future of Vaccines
Novavax applies to WHO for emergency listing of COVID-19 vaccine

$Salesforce (CRM.US)$ shares rose as much as 3% in extended trading on Wednesday after the enterprise software maker reported fiscal second-quarter earnings and forward guidance that exceeded analysts’ estimates.
Here’s how the company did:
Earnings: $1.48 per share, adjusted, vs. 92 cents per share expected by analysts, according to Refinitiv
Revenue: $6.34 billion, vs. $6.24 billion expected by analysts, according to Refinitiv
Revenue increased 23% YOY in the quarter, which ended July 31, the company said in a statement. In the prior quarter revenue grew 23%.
Salesforce signaled the shift to hybrid work would keep demand for its cloud-based software strong in the third quarter, after trumping market expectations for earnings in the May-July period.
The business software maker's revenue has gone...